MAMohammad Ahmadvand

Mohammad Ahmadvand

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Ahmadvand has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Mohammad Vaezi

    Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

    3 shared publications
  • Ahmadreza Mofayezi

    ReNAP Therapeutics, Tehran, Iran; Department of Biotechnology, University of Tehran, Tehran, Iran

    2 shared publications
  • Hossein Salehi-Shadkami

    ReNAP Therapeutics, Tehran, Iran; Department of Medical Science, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Maryam Barkhordar

    Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Masoumeh Alimohammadi

    ReNAP Therapeutics, Tehran, Iran

    2 shared publications
  • Mohammad Sadra Modaresi

    ReNAP Therapeutics, Tehran, Iran

    2 shared publications

Latest Publications

  • Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19⁺ primary B-ALL cells

    by Hossein Salehi-Shadkami, Mosslim Sedghi, Shima Tavoosi, Masoumeh Alimohammadi, Reza Alimohammadi, Maryam Barkhordar, Ahmadreza Mofayezi, Mohammad Sadra Modaresi, Mohammad Vaezi, Somaye Dehghanizadeh, et al.


  • Open Access

    Reduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines

    by Sahar Khojastehpour, Azarmidokht Aminazad, Shahrokh Abdolahi, Shirin Tavakoli, Maryam Samareh-Salavati, Nasrin Momeni, Mohammad Vaezi, Mohammad Ahmadvand

    Improving immune cell functions in tumors remains a main challenge in cancer immunotherapy. NK are main innate effector cells with anti-tumor activity against various tumors. Consequently, NK cells are proper candidates for cancer immunotherapy, including gastric cancer. The IL-15 signaling pathway is negatively regulated by a protein called Cish encoded by the Cish gene. In the present study, we explored the knockdown of Cish and anti-tumor effects of NK cells. We knockdown Cish in human primary NK cells using siRNA, and the expression of Cish was evaluated by qRT-PCR. Gene expression analysis revealed that Cish expression increased after induction by IL-15 at various time point and conversely decreased after knockdown, approximately 44% and 41% reduction were observed at siRNA concentrations of 100 nmol/l at timepoint of 6h and 48h, respectively. Cish knockdown of human NK cells, showed enhanced the anti-tumor effects and induced apoptosis against a human gastric cancer cell lines called MKN-45 and AGS. Additionally, co-culture with MKN-45 and AGS cells showed increased secretion of IFN-γ and TNF-ɑ that could be related to higher cytotoxicity of knockdown Cish NK cells. Our results indicate that Cish knockdown human NK cells enhanced cytotoxicity and cytokine production when co-cultured with gastric cancer cell lines. siRNA-mediated Cish knockdown NK cells, might be a promising immunotherapeutic alternative in patients with gastric cancer.


  • Open Access

    Effective targeting of CD19 positive primary B-ALL cells using CAR-NK cells generated with mRNA-LNPs

    by Hossein Salehi-Shadkami, Mosslim Sedghi, Shima Tavoosi, Masoumeh Alimohammadi, Reza Alimohammadi, Maryam Barkhordar, Ahmadreza Mofayezi, Mohammad Sadra Modaresi, Mohammad Vaezi, Somaye Dehghanizadeh, et al.

    1. Chimeric antigen receptor natural killer (CAR-NK) cell therapy is recognized as a promising modality for the treatment of hematologic malignancies, particularly B-cell malignancies. In this study, we developed “off-the-shelf” anti-CD19 CAR-NK cells using anti-CD19 CAR mRNAs formulated in proprietary ionizable lipid nanoparticles (LNPs). The efficiency of mRNA-LNP delivery into umbilical cord blood (UCB)-derived NK cells and primary T cells was evaluated in an in-vitro setting, demonstrating superior delivery efficiency in NK cells. Further investigation showed a probable role for an endocytic mechanism, macropinocytosis, in efficient transfection of NK cells with LNPs. Nevertheless, CAR-NK cells generated through this mRNA-LNP platform exhibited significantly enhanced cytotoxicity against CD19 + target cells, such as EGFP + Raji stable cell line and primary malignant B cells derived from refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL) patients. These findings highlight the promise of the mRNA-LNP platform in advancing CAR-NK therapies against B-cell malignancies.